CATB Catabasis Pharmaceuticals, Inc.

1.45
0  -6%
Previous Close 1.55
Open 1.61
Price To book 0.78
Market Cap 27.05M
Shares 18,652,000
Volume 1,244,376
Short Ratio 0.83
Av. Daily Volume 1,847,930

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia
Phase 1/2 Part B top-line data released January 31, 2017 - endpoint not met. Part C data due in 2017, with an interim update in 2Q.
CAT-1004
Duchenne muscular dystrophy (DMD)

Latest News

  1. Edited Transcript of CATB earnings conference call or presentation 16-Mar-17 8:30pm GMT
  2. Catabasis Pharmaceuticals posts 4Q loss
  3. CATABASIS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
  4. Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights
  5. Q4 2016 Catabasis Pharmaceuticals Inc Earnings Release - After Market Close
  6. Catabasis Pharmaceuticals to Present at Oppenheimer’s 27th Annual Healthcare Conference
  7. Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
  8. Catabasis Pharmaceuticals to Present at the 2017 Muscular Dystrophy Association Scientific Conference
  9. Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Developments on Thursday, March 16
  10. Catabasis Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference
  11. Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer
  12. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catabasis Pharmaceuticals, Inc.
  13. Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
  14. Catabasis Pharmaceuticals downgraded by Citigroup
  15. Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
  16. Catabasis Drops After Muscular Dystrophy Drug Fails
  17. Catabasis Pharmaceuticals Inc (CATB): What’s Next?
  18. Catabasis Pharma stock sinks 69% after negative mid-stage clinical trial results for DMD drug
  19. Catabasis shares plummet on Duchenne trial failure
  20. CATABASIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure